Rationale: Measuring the serological effects of the different vaccinations (immune surveillance) is an important tool for the evaluation of the National Immunisation Programme (NIP) by providing insight in the immune status of the population, by…
ID
Bron
Verkorte titel
Aandoening
The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population.
Achtergrond van het onderzoek
Measuring the serological effects of the different vaccinations (immune surveillance) is an important tool for the evaluation of the National Immunisation Programme (NIP) by providing insight in the immune status of the population, by identifying possible gaps in the immunity and subpopulations at risk and by assessing (re) emergence of disease. To obtain insight into the age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population, this observational study with a single invasive measurement (drawing of blood) and non-invasive measurement (saliva) is performed. For a subgroup, optional, a nose and throat swab will be collected as well as a faecal sample. A representative part sample of the Dutch population (age 0-89 years) is invited to participate. The age-specific seroprevalence (immunity) for diseases included in the NIP of the Dutch general population and against other infectious diseases, in particular those that
might be vaccine-preventable in the near future and against those diseases with a frequent
subclinical course, will be asessed.
Doel van het onderzoek
Rationale: Measuring the serological effects of the different vaccinations (immune surveillance) is an important tool for the evaluation of the National Immunisation Programme (NIP) by providing insight in the immune status of the population, by identifying possible gaps in the immunity and subpopulations at risk and by assessing (re) emergence of disease.
Onderzoeksopzet
A single time point for the collection of samples.
Onderzoeksproduct en/of interventie
None
Publiek
R.A.J. Boxtel, van
Bilthoven 3721 MA
The Netherlands
+31 (0)30 2742755
renee.van.boxtel@rivm.nl
Wetenschappelijk
R.A.J. Boxtel, van
Bilthoven 3721 MA
The Netherlands
+31 (0)30 2742755
renee.van.boxtel@rivm.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• Subject is part of the national study sample drawn from the population register, aged 0 to 89 year old and has received a personal invitation for the PIENTER study.
• Subject has given written Informed Consent (IC) before the start of the study visit.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
None
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL5467 |
| NTR-old | NTR5611 |
| Ander register | NL54228.094.15 : IIV-284 |
Samenvatting resultaten
Mollema L, de Melker HE, Hahné SJM, van Weert JWM, Berbers GAM, van der Klis FRM. PIENTER 2 project: second research project on the protection against infectious diseases offered by the national immunization programme in the Netherlands. RIVM report 230421001/2009.<br>
PIENTER2 study 2006-2007: A summary of the main findings. Van der Klis FRM, Mollema L, van Weert JWM. RIVM report, April 2012.